Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir in Pediatric Kidney Transplant Recipients
NCT07199465Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of letermovir in cytomegalovirus infection (CMV), sponsored by Merck & Co. Primary endpoint: Area Under the Curve From Time 0 to 24 Hours. Started Mar 2026; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07199465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199465.